Medicash has confirmed its 1,000th clinically validated case of skin cancer among its policyholders since partnering with SkinVision in 2020.
Medicash says its partnership with SkinVision marks a milestone in providing tools for early detection and proactive healthcare through digital innovations.
Since 2020, Medicash policyholders have used SkinVision to monitor their skin health remotely.
The app enables users to monitor moles and skin lesions by submitting photos for risk assessments based on clinical criteria, with dermatologists verifying the results. It aims to help identify potential issues sooner, supporting quicker diagnoses and improved health outcomes by encouraging early intervention.
According to Medicash, this achievement highlights its use of digital health innovations to support preventative care and skin health. It also adds that the partnership aims to provide cost-effective, accessible wellbeing solutions for policyholders to manage their health proactively.
Medicash chief executive Sue Weir says: “This milestone reflects the effectiveness of our partnership with SkinVision in making skin health assessment more accessible and potentially life-saving. With skin cancer rates on the rise, particularly in the UK, it is essential that our policyholders have the tools to identify potential issues as early as possible.
“Our collaboration with SkinVision is a powerful example of how technology can improve wellbeing outcomes, ultimately transforming lives and strengthening healthcare support.”
